CO6321240A2 - Compuestos de anillo fusionados como activadores de glucocinasa - Google Patents

Compuestos de anillo fusionados como activadores de glucocinasa

Info

Publication number
CO6321240A2
CO6321240A2 CO10140654A CO10140654A CO6321240A2 CO 6321240 A2 CO6321240 A2 CO 6321240A2 CO 10140654 A CO10140654 A CO 10140654A CO 10140654 A CO10140654 A CO 10140654A CO 6321240 A2 CO6321240 A2 CO 6321240A2
Authority
CO
Colombia
Prior art keywords
fusioned
ring compounds
glucocinase
activators
glucocinase activators
Prior art date
Application number
CO10140654A
Other languages
English (en)
Inventor
Tsuneo Yasuma
Nobuyuki Takakura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CO6321240A2 publication Critical patent/CO6321240A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La presente invención proporciona un activador de glucocinasa útil como un agente farmacéutico tal como un agente para la profilaxis o tratamiento de diabetes, obesidad y similares. La presente invención proporciona un activador de glucocinasa que contiene un compuesto representado por la fórmula (I): en donde cada símbolo se define en la especificación, o una sal del mismo o un profármaco del mismo.
CO10140654A 2008-04-10 2010-11-10 Compuestos de anillo fusionados como activadores de glucocinasa CO6321240A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008102691 2008-04-10

Publications (1)

Publication Number Publication Date
CO6321240A2 true CO6321240A2 (es) 2011-09-20

Family

ID=40671202

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10140654A CO6321240A2 (es) 2008-04-10 2010-11-10 Compuestos de anillo fusionados como activadores de glucocinasa

Country Status (35)

Country Link
US (1) US8673942B2 (es)
EP (1) EP2276760B1 (es)
JP (1) JP5528348B2 (es)
KR (1) KR20110002472A (es)
CN (1) CN102056924B (es)
AR (1) AR073609A1 (es)
AU (1) AU2009234666B2 (es)
BR (1) BRPI0910912A2 (es)
CA (1) CA2720686A1 (es)
CO (1) CO6321240A2 (es)
CR (1) CR11730A (es)
CY (1) CY1115247T1 (es)
DK (1) DK2276760T3 (es)
DO (1) DOP2010000301A (es)
EA (1) EA019640B1 (es)
EC (1) ECSP10010602A (es)
ES (1) ES2476265T3 (es)
GE (1) GEP20135846B (es)
HK (1) HK1152932A1 (es)
HR (1) HRP20140588T1 (es)
IL (1) IL208463A (es)
MA (1) MA32283B1 (es)
ME (1) ME01887B (es)
MX (1) MX2010011138A (es)
MY (1) MY152475A (es)
NZ (1) NZ588562A (es)
PE (1) PE20100734A1 (es)
PL (1) PL2276760T3 (es)
PT (1) PT2276760E (es)
RS (1) RS53378B (es)
SI (1) SI2276760T1 (es)
UA (1) UA104422C2 (es)
UY (1) UY32131A (es)
WO (1) WO2009125873A1 (es)
ZA (1) ZA201007682B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010076884A1 (ja) 2008-12-29 2010-07-08 武田薬品工業株式会社 新規縮合環化合物およびその用途
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
US9453038B2 (en) 2012-12-17 2016-09-27 Merck Sharp & Dohme Corp. Glucokinase activator compounds, compositions containing such compounds, and methods of treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05505612A (ja) 1991-03-01 1993-08-19 ハー・ルンドベック・アクティーゼルスカブ 高血圧症及び末梢血管疾患の治療法
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
CN101103977A (zh) 2002-06-05 2008-01-16 株式会社医药分子设计研究所 糖尿病治疗药
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
WO2006089397A1 (en) 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Methods for treating arthritis using triheterocyclic compounds
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US7799820B2 (en) 2005-09-30 2010-09-21 Banyu Pharmaceutical Co., Ltd. 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions
KR101444486B1 (ko) 2006-10-19 2014-09-24 다케다 야쿠힌 고교 가부시키가이샤 인돌 화합물
JP5323834B2 (ja) 2007-08-17 2013-10-23 エルジー・ライフ・サイエンシーズ・リミテッド 細胞壊死阻害剤としてのインドール化合物
CN101896483B (zh) 2007-12-20 2013-11-20 株式会社Lg生命科学 葡糖激酶激活剂和包含其作为活性成分的药物组合物
JP5188583B2 (ja) * 2008-01-04 2013-04-24 エルジー・ライフ・サイエンシーズ・リミテッド 細胞、組織及び臓器保存効果を有するインドール及びインダゾール誘導体
WO2010076884A1 (ja) 2008-12-29 2010-07-08 武田薬品工業株式会社 新規縮合環化合物およびその用途

Also Published As

Publication number Publication date
JP5528348B2 (ja) 2014-06-25
IL208463A0 (en) 2010-12-30
ES2476265T3 (es) 2014-07-14
DK2276760T3 (da) 2014-05-26
EP2276760A1 (en) 2011-01-26
AU2009234666B2 (en) 2014-02-20
PL2276760T3 (pl) 2014-09-30
EP2276760B1 (en) 2014-04-09
UA104422C2 (uk) 2014-02-10
JP2011516403A (ja) 2011-05-26
BRPI0910912A2 (pt) 2015-08-11
PE20100734A1 (es) 2010-11-18
WO2009125873A1 (en) 2009-10-15
HK1152932A1 (en) 2012-03-16
DOP2010000301A (es) 2010-12-31
NZ588562A (en) 2012-07-27
CN102056924B (zh) 2014-05-21
KR20110002472A (ko) 2011-01-07
AU2009234666A1 (en) 2009-10-15
CN102056924A (zh) 2011-05-11
GEP20135846B (en) 2013-06-10
SI2276760T1 (sl) 2014-05-30
US20110098297A1 (en) 2011-04-28
RS53378B (en) 2014-10-31
ME01887B (me) 2014-12-20
MA32283B1 (fr) 2011-05-02
CR11730A (es) 2010-12-08
MX2010011138A (es) 2010-11-12
ECSP10010602A (es) 2011-03-31
MY152475A (en) 2014-10-15
UY32131A (es) 2010-11-30
ZA201007682B (en) 2011-12-28
IL208463A (en) 2015-07-30
HRP20140588T1 (hr) 2014-08-01
PT2276760E (pt) 2014-05-28
EA019640B1 (ru) 2014-05-30
CY1115247T1 (el) 2017-01-04
US8673942B2 (en) 2014-03-18
CA2720686A1 (en) 2009-10-15
EA201071180A1 (ru) 2011-04-29
AR073609A1 (es) 2010-11-17

Similar Documents

Publication Publication Date Title
CO6321240A2 (es) Compuestos de anillo fusionados como activadores de glucocinasa
ECSP099330A (es) Compuesto de indol
CR10564A (es) Compuestos cíclicos fusionados
DOP2013000118A (es) Compuesto bicíclico
ECSP12011573A (es) Compuestos tetracíclicos
DOP2010000267A (es) Compuesto heterociclico
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
ECSP099552A (es) Compuestos triciclicos, composiciones y procedimientos
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
BR112012032087A2 (pt) composto, medicamento, e, uso de um composto
AR087451A1 (es) Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
CR10524A (es) Compuesto triciclico y uso farmaceutico del mismo
CR11613A (es) Asociacion entre una sal de bis-tiazolio o uno de sus precursores y artemisinina o uno de sus derivados para el tratamiento del paludismo grave
BR112017005241A2 (pt) composto, e, composição farmacêutica.
AR118361A2 (es) Sales monoclorhidrato de un inhibidor de histona deacetilasa
TN2011000294A1 (en) Arylcyclopropylacetamide derivatives useful as glucokinase activators
DOP2009000081A (es) Compuesto de indol
TN2010000450A1 (en) Fused ring compounds and use thereof
UY35095A (es) Compuestos heterocíclicos que contienen nitrógeno
TN2010000397A1 (en) Heterocyclic compounds
NI200900185A (es) Sales monoclohidrato de un inhibidor de histona deacetilasa
UY32088A (es) Compuesto heterociclico

Legal Events

Date Code Title Description
FG Application granted